生命科学2025-权威的全球法律指南_提供顶级律师的比较分析（英）-2025_23页_1mb

报告摘要

Key Legislation: Drugs and Cosmetics Act, 1940 (primary legislation), Drugs Rules, 1945, Medical Devices Rules, 2017, New Drugs and Clinical Trial Rules, 2019, Hazardous and Other Wastes Rules, 2016, etc. Drugs also subject to other laws (e.g., Narcotic Drugs Act, DMRA).
Medical Devices: Regulated under Drugs Rules since DCA considers them 'drugs'. India requires adherence to DCGI classification (cannot be self-classified like some other countries). Foreign marketing approvals may waive local trials under certain conditions (waiver discretionary).
Regulatory Bodies: CDSCO/DCGI (central level), State Licensing Authorities (SLAs), NPPA (price control), IPC (Pharmacopoeia standards). Competent Authorities (CLAs/SLAs) decisions can be appealed via regulatory processes.
Classification: Drugs regulated based on schedules (e.g., biological products, prescription vs OTC (not explicitly recognized)). Devices classified by risk (A-D), DCGI determines classification which impacts regulations ('blue sky thinking' is key).

Regulation: Governed by New Drugs and Clinical Trial Rules, 2019. Registration mandatory with CTRI before participant enrolment and periodic updates required after phases.
Protocol Approval: Requires Ethics Committee (EC) approval. Clinical Investigation plans (pilot/pivotal) require CDSCO/DCGI approval after EC approval.
Permissions: CDSCO/DCGI reviews applications for clinical investigation permissions, setting conditions including GCP adherence, reporting Serious Adverse Events (SAEs), site inspections, and warranty of timely enrolment.
Online Tools: Regulations (NDCTR/MDR) don't explicitly prohibit online tools but approval protocols must detail their use, reviewed by EC (data protection evolving with DPDPA/DPDP Rules).
Data Protection: Personal/health data subject to SPDI Rules/DPDPA. Consent required; transfer restricted unless permitted in DPDP Rules. Suspected SAEs require medical management and compensation.

Pharmaceuticals:
- Classification: Trigger DCA framework if disease diagnosis/treatment. Further categorised (biological, special, etc.) impacting regulations indefinitely unless reclassified.
- New/Unapproved Drugs: Authorization requires local trials unless waived. Biologicals must undergo review (NPPA, etc.). Grants marketing permission (COP) non-transferrable; manufacturing/import licenses separate.
- Fast Track/Reliance: No automatic reliance; CLA can waive clinical requirements (abbreviate/defer data) for critical conditions based on foreign approvals.
- Post-Marketing: Pharmacovigilance (SAE reporting, PSURs) mandatory. Limited HTA used in pricing/policy decisions.
Medical Devices:
- Classification/Regulation: Based on risk (A-D), managed by CLA/DCGI. Good Manufacturing Practices (GMP) and ISO 14385 required, inspection varies by class.
- Authorization: Import license required. Pre-facto/Post-approval site inspections possible. Registration certificate needed.
- Post-Marketing: Technovigilance (SAE reporting, PSURs) mandatory. Pre/Post-approval follow-up clinical data may be needed for unique devices.

Regulatory reliance not formally standardised in India.
CLA can exercise discretion to abbreviate, defer, or waive clinical requirements for critical medical devices (life-threatening, epidemic scenarios).
Import/distribution licensing requirements trigger under Foreign Trade Act, 1992, Customs Act, 1962, establishing importer-of-record obligations.

Pharmaceuticals: GMP compliance mandatory. Separate authorization needed for manufacturing (often via import license) subject to regulatory standards (Drugs Rules/WHO-GMP). Domestic sites require prior inspection/SLA certification typically.
Medical Devices: Quality Management Systems and GMP compliance mandatory (MDR Rule implementation/documented evidence for pre-existing devices). Process differing by device classification (A/B - review less invasive, C/D - inspection likely).

Wholesale: Requires SLA-issued license (central/federal/fixed for period). Requirements depend on drug categories.
Medical Devices: Typically require MDR permits. Evidence chains (freight forwarders, customs, temperature monitoring) importance highlighted for transport and storage.

Import: DCA/MDR frameworks. Requires registration certificate + import license for most drugs/devices. Licenses required for public interest, clinical trials waived in some cases. Importer-of-record must be licensed to sell/wholesale in India. Wharf-to-wharf delivery rules (ITHS codes, IEC mandatory).
Export Controls: Manufacturing/wholesale controls primarily based on domestic regulations. Narcotic/drug restrictions trigger via special acts.
Trade Blocs: Validated in various agreements impacting pharmaceutical trade access.

Price Control: DPCO dictates price ceiling for National List Essentials (NLEM). MRPs set (ceiling + taxes) for others. DPPA monitors price increases (max 10% per year) and sets regulated prices extralegally. Trade margin rationalisation increasingly used (caps retailer margin). Prices independent per product.
Reimbursement: Limited public fund reimbursement (Ayushman Bharat, etc.) generally tied to hospitalization. Out-of-pocket patient cost common. HTA not formally integrated for pricing yet.
Regulation: Focus on manufacturer pricing setting via DPCO ceiling. Limited regulation on prescribing/dispensing stages (generic prescribing encouraged, but not robustly enforced).

展开完整摘要